• About Us
    • About Neurocrine
    • Leadership Team
      • Management Team
      • Board of Directors
    • Culture & Values
      • Patient Access & Pricing
      • Diversity & Equality
    • News & Events
    • Webcasts & Presentations
    • Contact Us
  • Patients & Families
    • Overview
    • Tardive Dyskinesia
    • Parkinson’s Disease
    • Congenital Adrenal Hyperplasia
    • Chorea in Huntington Disease
    • Women’s Health
    • Psychiatry
      • Schizophrenia
      • Treatment-Resistant Depression
      • Anhedonia
  • Products
  • Pipeline
    • OVERVIEW
    • Parkinson’s Disease
      • NBIb-1817
        • Clinical Trials
    • Congenital Adrenal Hyperplasia
      • Crinecerfont
        • Clinical Trials
    • Chorea in Huntington Disease
      • Valbenazine
        • Clinical Trials
    • Women’s Health
      • Polycystic Ovary Syndrome
    • Additional Pipeline Programs
    • Psychiatry
      • Schizophrenia
        • NBI-1065844
          • Clinical Trials
      • Treatment-Resistant Depression
        • NBI-1065845
      • Anhedonia
        • NBI-1065846
  • Careers
    • Overview
    • Culture and Values
    • Benefits
    • Recruitment Agencies
  • Investors
    • Press Releases
    • Stock Quote
    • SEC Filings
    • Shareholder Contacts
    • Partners/Collaborators
    • Annual Meeting
    • Online Annual Reports
    • Ownership
    • Email Alerts
    • Corporate Governance
    • Corporate Sustainability
    • Webcasts & Presentations
  • Contact Us

Corporate Sustainability

 

Click Below For Neurocrine Biosciences’ Approach to Environment, Social and Governance (ESG) Programs

Neurocrine Biosciences 2020 ESG Report

Investors

  • Press Releases
  • Stock Quote
  • SEC Filings
  • Shareholder Contacts
  • Partners/Collaborators
  • Annual Meeting
  • Online Annual Reports
  • Ownership
  • Email Alerts
  • Corporate Governance
  • Corporate Sustainability
  • Webcasts & Presentations
  • ©2019 Neurocrine Biosciences, Inc.
  • All Rights Reserved.
  • Privacy Policy
  • Cookie Policy
  • Terms & Conditions
  • Sitemap
  • CP-NBI-US-0022 02/17

You are now leaving the Neurocrine website.

Neurocrine is not responsible for the content of linked third party websites. Please be aware that the privacy policies and terms of use on these sites are different from Neurocrine policies.

Leave Site

By continuing to use this site, you agree to our use of cookies
as described in our Cookie Policy.